Počet záznamů: 1  

Novel Inhibitors of Cyclin-Dependent Kinases Combat Hepatocellular Carcinoma without Inducing Chemoresistance

  1. 1.
    SYSNO ASEP0421049
    Druh ASEPJ - Článek v odborném periodiku
    Zařazení RIVJ - Článek v odborném periodiku
    Poddruh JČlánek ve WOS
    NázevNovel Inhibitors of Cyclin-Dependent Kinases Combat Hepatocellular Carcinoma without Inducing Chemoresistance
    Tvůrce(i) Haider, C. (AT)
    Grubinger, M. (AT)
    Řezníčková, Eva (UEB-Q) RID, ORCID
    Weiss, T.S. (DE)
    Rotheneder, H. (AT)
    Miklos, W. (AT)
    Berger, W. (AT)
    Jorda, Radek (UEB-Q) ORCID, RID
    Zatloukal, M. (CZ)
    Gucký, T. (CZ)
    Strnad, Miroslav (UEB-Q) RID, ORCID
    Kryštof, Vladimír (UEB-Q) RID, ORCID
    Mikulits, W. (AT)
    Zdroj.dok.Molecular Cancer Therapeutics. - : American Association for Cancer Research - ISSN 1535-7163
    Roč. 12, č. 10 (2013), s. 1947-1957
    Poč.str.11 s.
    Jazyk dok.eng - angličtina
    Země vyd.US - Spojené státy americké
    Klíč. slovaPRIMARY HUMAN HEPATOCYTES ; SELICICLIB R-ROSCOVITINE ; CELL-CYCLE
    Vědní obor RIVCE - Biochemie
    CEPGAP305/12/0783 GA ČR - Grantová agentura ČR
    GA301/08/1649 GA ČR - Grantová agentura ČR
    CEZAV0Z50380511 - UEB-Q (2005-2011)
    UT WOS000325548400003
    DOI10.1158/1535-7163.MCT-13-0263
    AnotaceTreatment options for hepatocellular carcinoma using chemotherapeutics at intermediate and advanced stages of disease are limited as patients most rapidly escape from therapy and succumb to disease progression. Mechanisms of the hepatic xenobiotic metabolism are mostly involved in providing chemoresistance to therapeutic compounds. Given the fact that the aberrant activation of cyclin-dependent kinases (CDK) is frequently observed in hepatocellular carcinomas, we focused on the efficacy of the novel compounds BA-12 and BP-14 that antagonize CDK1/2/5/7 and CDK9. Inhibition of those CDKs in human hepatocellular carcinoma cell lines reduced the clonogenicity by arresting cells in S-G(2) and G(2)-M phase of the cell cycle and inducing apoptosis. In contrast, primary human hepatocytes failed to show cytotoxicity and apoptosis. No loss of chemosensitivity was observed in hepatocellular carcinoma cells after long-term exposure to inhibitors. In vivo, treatment of xenografted human hepatocellular carcinomas with BA-12 or BP-14 effectively repressed tumor formation. Moreover, BA-12 or BP-14 significantly diminished diethylnitrosamine (DEN)-induced hepatoma development in mice. These data show that BA-12 or BP-14 exhibit strong antitumorigenic effects in the absence of chemoresistance, resulting in a superior efficacy compared with currently used chemotherapeutics in hepatocellular carcinomas.
    PracovištěÚstav experimentální botaniky
    KontaktDavid Klier, knihovna@ueb.cas.cz, Tel.: 220 390 469
    Rok sběru2014
Počet záznamů: 1  

  Tyto stránky využívají soubory cookies, které usnadňují jejich prohlížení. Další informace o tom jak používáme cookies.